Management of Graves Thyroidal and Extrathyroidal Disease: An Update
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Context: Invited update on the management of systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO). Evidence acquisition: Guidelines, pertinent original articles, systemic reviews, and meta-analyses. Evidence synthesis: Thyrotropin receptor antibodies (TSH-R-Abs), foremost the stimulatory TSH-R-Abs, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug. Patients with persistently high TSH-R-Abs and/or persistent hyperthyroidism at 18 months, or with a relapse after completing a course of MMI, can opt for a definitive therapy with radioactive iodine (RAI) or total thyroidectomy (TX). Continued long-term, low-dose MMI administration is a valuable and safe alternative. Patient choice, both at initial presentation of GD and at recurrence, should be emphasized. Propylthiouracil is preferred to MMI during the first trimester of pregnancy. TX is best performed by a high-volume thyroid surgeon. RAI should be avoided in GD patients with active GO, especially in smokers. Recently, a promising therapy with an anti-insulin-like growth factor-1 monoclonal antibody for patients with active/severe GO was approved by the Food and Drug Administration. COVID-19 infection is a risk factor for poorly controlled hyperthyroidism, which contributes to the infection–related mortality risk. If GO is not severe, systemic steroid treatment should be postponed during COVID-19 while local treatment and preventive measures are offered. Conclusions: A clear trend towards serological diagnosis and medical treatment of GD has emerged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Cooper, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra042972 · Cited by 1,008
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationThe American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Life-Threatening Thyrotoxicosis: Thyroid Storm
Burch, H. B., & Wartofsky, L. (1993) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30165-8 · Cited by 852 · cited 1×
“The inhibition of the T4 deiodination and the lower placental transfer and less severe PTU-caused embryopathy explain why PTU is the first-line therapy of both thyroid storm in GD as well as in the first 10 to 12 weeks of pregnancy (77-79).”
BackgroundRelation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715 · cited 1×
“This is mainly because RAI is associated with both sustained increases in TSH-R-Ab titers after RAI and a definite risk for a de novo GO and/or exacerbation of the clinical activity and severity of the orbital disease (55-62).”
BackgroundSubclinical hyperthyroidism and the risk of coronary heart disease and mortality
Collet, T.-H., Gussekloo, J., Bauer, D. C., den Elzen, W. P. J., Cappola, A. R., Balmer, P., Iervasi, G., Åsvold, B. O., Sgarbi, J. A., Völzke, H., et al. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.402 · Cited by 572
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521 · cited 1×
“This is mainly because RAI is associated with both sustained increases in TSH-R-Ab titers after RAI and a definite risk for a de novo GO and/or exacerbation of the clinical activity and severity of the orbital disease (55-62).”
BackgroundGencer, B., Collet, T.-H., Virgini, V., Bauer, D. C., Gussekloo, J., Cappola, A. R., Nanchen, D., den Elzen, W. P. J., Balmer, P., Luben, R. N., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.096024 · Cited by 517
Laurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0450 · Cited by 428 · cited 1×
“This is mainly because RAI is associated with both sustained increases in TSH-R-Ab titers after RAI and a definite risk for a de novo GO and/or exacerbation of the clinical activity and severity of the orbital disease (55-62).”
BackgroundApplications of a New Chemiluminometric Thyrotropin Assay to Subnormal Measurement*
SPENCER, C. A., LoPRESTI, J. S., PATEL, A., GUTTLER, R. B., EIGEN, A., SHEN, D., GRAY, D., & NICOLOFF, J. T. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-2-453 · Cited by 371 · cited 2×
“Additional assessment of the free thyroid hormones differentiates between overt and subclinical hyperthyroidism (21).”
BackgroundLAURBERG, P., PEDERSEN, K. M., VESTERGAARD, H., & SIGURDSSON, G. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00368.x · Cited by 361
Subclinical Thyroid Dysfunction and Fracture Risk: A Meta-analysis
Blum, M. R., Bauer, D. C., Collet, T.-H., Fink, H. A., Cappola, A. R., da Costa, B. R., Wirth, C. D., Peeters, R. P., Åsvold, B. O., den Elzen, W. P. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.5161 · Cited by 343
Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J. (2015) · European Thyroid Journal · doi:10.1159/000438750 · Cited by 323
Self-citationCooper, D. S., & Laurberg, P. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70086-x · Cited by 310 · cited 2×
“The inhibition of the T4 deiodination and the lower placental transfer and less severe PTU-caused embryopathy explain why PTU is the first-line therapy of both thyroid storm in GD as well as in the first 10 to 12 weeks of pregnancy (77-79).”
BackgroundVITTI, P., RAGO, T., CHIOVATO, L., PALLINI, S., SANTINI, F., FIORE, E., ROCCHI, R., MARTINO, E., & PINCHERA, A. (1997) · Thyroid · doi:10.1089/thy.1997.7.369 · Cited by 293
Nakamura, H., Noh, J. Y., Itoh, K., Fukata, S., Miyauchi, A., Hamada, N., & Working Group of the Japan Thyroid Association for the Guideline of the Treatment of Graves’ Disease (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2135 · Cited by 277 · cited 1×
“Cutaneous reactions to ATD occur early during therapy (92).”
BackgroundBirth Defects After Early Pregnancy Use of Antithyroid Drugs: A Danish Nationwide Study
Andersen, S. L., Olsen, J., Wu, C. S., & Laurberg, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2831 · Cited by 267 · cited 2×
“The inhibition of the T4 deiodination and the lower placental transfer and less severe PTU-caused embryopathy explain why PTU is the first-line therapy of both thyroid storm in GD as well as in the first 10 to 12 weeks of pregnancy (77-79).”
BackgroundTräisk, F., Tallstedt, L., Abraham-Nordling, M., Andersson, T., Berg, G., Calissendorff, J., Hallengren, B., Hedner, P., Lantz, M., Nyström, E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0747 · Cited by 262
Antithyroid drug regimen for treating Graves’ hyperthyroidism
Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F., & Bevan, J. S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003420.pub4 · Cited by 249
Cardiovascular involvement in patients with different causes of hyperthyroidism
Biondi, B., & Kahaly, G. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.105 · Cited by 230 · cited 3×
“Uncontrolled thyrotoxicosis is associated with excess cardiovascular mortality (136, 201).”
BackgroundSelf-citationTozzoli, R., Bagnasco, M., Giavarina, D., & Bizzaro, N. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.003 · Cited by 195 · cited 1×
“The conventional TSH-R-Ab binding immunoassays are sensitive and specific (98 and 99%, respectively); however, these assays do not differentiate between Ab functionality (24, 25).”
BackgroundClinical associations between thyroid and liver diseases
HUANG, M., & LIAW, Y. (1995) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1995.tb01106.x · Cited by 186 · cited 15×
“PTU-induced vasculitis often occurs after years of treatment and is associated with perinuclear anticytoplasmic neutrophil antibodies (106).”
BackgroundInfluentialAnalysis of 754 Cases of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in Japan
Nakamura, H., Miyauchi, A., Miyawaki, N., & Imagawa, J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2569 · Cited by 180
Radioiodine-induced thyroid storm
McDermott, M. T., Kidd, G. S., Dodson, L. E., & Hofeldt, F. D. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)91217-2 · Cited by 163
Tajiri, J. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390150107020 · Cited by 156 · cited 1×
“5% of patients taking ATDs, foremost within 3 months after the start of therapy (96, 97).”
BackgroundVariation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel.
McLeod, D. S. A., Caturegli, P., Cooper, D. S., Matos, P. G., & Hutfless, S. (2014) · JAMA · doi:10.1001/jama.2013.285606 · Cited by 128 · cited 1×
“An increased incidence is observed among African Americans (5).”
BackgroundLaurberg, P., & Andersen, S. L. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0135 · Cited by 115 · cited 2×
“The critical time interval for exposure of the fetus is between week 5 to 6 and week 10 (115-119).”
BackgroundAntithyroid drug‐related hepatotoxicity in hyperthyroidism patients: a population‐based cohort study
Wang, M., Lee, W., Huang, T., Chu, C., & Hsieh, C. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12336 · Cited by 114 · cited 15×
“PTU-induced vasculitis often occurs after years of treatment and is associated with perinuclear anticytoplasmic neutrophil antibodies (106).”
BackgroundInfluentialMaternal and perinatal outcome in thyrotoxicosis complicating pregnancy
Kriplani, A., Buckshee, K., Bhargava, V. L., Takkar, D., & Ammini, A. C. (1994) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(94)90276-3 · Cited by 104 · cited 1×
“2% of pregnancies and increases the risk of adverse outcomes in both mother and child (78, 111-114).”
Backgroundde los Santos, E. T. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390030032006 · Cited by 92 · cited 1×
“The measurement of serum baseline TSH is the acknowledged screening parameter in the initial evaluation of suspected thyroid dysfunction (19-21).”
BackgroundKahaly, G. J., Bartalena, L., & Hegedüs, L. (2011) · Thyroid® · doi:10.1089/thy.2011.2106.ed3 · Cited by 80
Self-citationSato, S., Noh, J. Y., Sato, S., Suzuki, M., Yasuda, S., Matsumoto, M., Kunii, Y., Mukasa, K., Sugino, K., Ito, K., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0084 · Cited by 67
Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study
Oltmann, S. C., Brekke, A. V., Schneider, D. F., Schaefer, S. C., Chen, H., & Sippel, R. S. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4077-8 · Cited by 65 · cited 1×
“Calcium substitution substantially lowers the risks of perioperative hypocalcemia (156, 157).”
BackgroundBalavoine, A.-S., Glinoer, D., Dubucquoi, S., & Wémeau, J.-L. (2015) · Thyroid® · doi:10.1089/thy.2014.0603 · Cited by 65
Analysis of 90 Cases of Antithyroid Drug-Induced Severe Hepatotoxicity Over 13 Years in China
Yang, J., Li, L.-F., Xu, Q., Zhang, J., Weng, W.-W., Zhu, Y.-J., & Dong, M.-J. (2015) · Thyroid · doi:10.1089/thy.2014.0350 · Cited by 60
Andrade, V. A., Gross, J. L., & Maia, A. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6149 · Cited by 53
Di Donna, V., Santoro, M. G., de Waure, C., Ricciato, M. P., Paragliola, R. M., Pontecorvi, A., & Corsello, S. M. (2014) · Thyroid · doi:10.1089/thy.2014.0111 · Cited by 52
Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis
Hieu, T. T., Russell, A. W., Cuneo, R., Clark, J., Kron, T., Hall, P., & Doi, S. A. R. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0176 · Cited by 50 · cited 1×
“This was inconclusive for those treated with RAI for hyperthyroidism (144-146).”
BackgroundBioassays for TSH Receptor Antibodies: Quo Vadis?
Kahaly, G. J. (2015) · European Thyroid Journal · doi:10.1159/000375445 · Cited by 41
Self-citationJespersen, S., Nygaard, B., & Kristensen, L. Ø. (2015) · European Thyroid Journal · doi:10.1159/000440834 · Cited by 22
Cited by
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationMultifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Metadata
- Authors
- Kahaly, G. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-09-14
- Volume
- 105
- Issue
- 12
- Pages
- 3704-3720
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3085560214
- Cited by
- 223
- References
- 44
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.